More and more clinical guidelines have recommended use of sodium-glucose cotransporter-2 (SGLT2) inhibitors, also known as gliflozins, to prevent major adverse cardiovascular and renal events in patients with type 2 diabetes, heart failure, and/or chronic kidney disease. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.